RHOA and angioimmunoblastic T-cell lymphoma: To test this hypothesis, we assessed RHOA mutations in younger patients with AITL RHOA mutations were detected in 65% of the younger AITL group, with no significant difference between EBER+ (62%) and EBV− (70%) status.